Redcare Pharmacy stock tests 2026 margin path as targets hold

Redcare Pharmacy's third-quarter performance strengthened the growth case, but the company's confirmed 2026 targets leave profitability as the key test. In its October 29 release, Redcare Pharmacy reported higher revenue, strong prescription growth and an improved adjusted EBITDA margin.

Growth Raises the Profitability Test

Group revenue rose 18% year over year to EUR 847 million in the third quarter of 2026. Rx revenue increased 31%, led by a 56% increase in Germany, while non-Rx revenue grew 9%.

Adjusted EBITDA climbed 68% to EUR 28.7 million, lifting the margin to 3.4% from 2.4% a year earlier. The company also reported a net profit for the second consecutive quarter and an active customer base of 15.2 million at the end of September.

Guidance Leaves Little Room for Slippage

Redcare confirmed full-year revenue growth of 16% to 18% and an adjusted EBITDA margin of 2.5% to 3.0%. German Rx revenue is expected to reach EUR 730 million to EUR 760 million, equivalent to growth of 45% to 51%.

The operating setup remains mixed. Prescription demand is expanding rapidly, while competition and softer non-prescription momentum could pressure marketing efficiency and margins. For investors, the next proof point is whether scale gains continue to translate into durable profitability.

Share Price Moves Beyond the Xetra Close

Redcare Pharmacy stock traded at EUR 70.35 on Lang & Schwarz at 18:12 CET on Thursday, November 12, 2026, 0.43% above the Xetra close of Thursday, November 12, 2026. The quote was EUR 71.20 at 11:09 CET in the latest relevant own article, making the later price 1.19% lower.

European equity markets remain an important backdrop for valuation and risk appetite; see Current market reports.

Further company-specific developments are collected under More news and analyses on Redcare Pharmacy stock.